Journal Article

Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: a case report and literature review

Mullikin, Dolores, Bryan, Angela, Moser, Sam, Stewart, J. Alex, Price, Theresa

2022

Overview

Background Macrophage activation syndrome (MAS) is a severe and under-recognized complication of rheumatologic diseases. We describe a patient who presented with rapidly progressive, refractory MAS found to have anti-MDA5 antibody Juvenile Dermatomyositis (JDM) as her underlying rheumatologic diagnosis. Case presentation We describe a 14-year-old female who at the time of admission had a history of daily fevers for 6 weeks and an unintentional sixteen-pound weight loss. Review of systems was significant for cough, shortness of breath, chest pain, headaches, sore throat, muscle aches, rash, nausea, and loss of appetite. An extensive initial workup revealed findings consistent with an autoimmune process. While awaiting results of her workup she had clinical decompensation with multi-organ system involvement including pancytopenias, interstitial lung disease, hepatitis, cardiac involvement, gastrointestinal distension and pain, feeding intolerance, extensive mucocutaneous candidiasis, and neuropsychiatric decline. Due to her decompensation, significant interstitial lung disease, and likely underlying rheumatologic condition she was started on high dose pulse steroids and mycophenolate. An MRI was performed due to her transaminitis and shoulder pain revealing significant myositis. Intravenous immunoglobulin was then initiated. The myositis antibody panel sent early in her workup was significant for anti-MDA5 and anti-SSA-52 antibodies. Despite high dose pulse steroids, mycophenolate, and IVIG, her disease progressed requiring escalating therapies. Ultimately, she responded with resolution of her MAS as well as significant and steady improvement in her feeding intolerance, interstitial lung disease, cardiac dysfunction, myositis, arthritis, and cutaneous findings. Conclusions JDM in the pediatric patient is rare, as is MAS. In patients with complex rheumatologic conditions and lack of response to treatment, it is important to continually assess the patient’s clinical status with MAS in mind, as this may change the treatment approach. Without proper recognition of this complication, patients can have a significant delay in diagnosis leading to life-threatening consequences.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Adolescent / Antibodies / Atrial fibrillation / Autoantibodies - blood / Case Report / Caspofungin / Children / Clinical Deterioration / Dermatomyositis / Dermatomyositis - complications / Dermatomyositis - diagnosis / Dermatomyositis - immunology / Development and progression / Dose-Response Relationship, Immunologic / Female / Glucocorticoids - administration & dosage / Health aspects / Humans / Hyperferritinemia / Idiopathic inflammatory myopathy / Immunoglobulins, Intravenous - administration & dosage / Immunologic Factors - administration & dosage / Immunosuppressive agents / Interferon-Induced Helicase, IFIH1 - immunology / Lung diseases / Macrophage Activation Syndrome - diagnosis / Macrophage Activation Syndrome - etiology / Macrophage Activation Syndrome - immunology / Macrophages / Magnetic Resonance Imaging - methods / Medical research / Medicine / Medicine & Public Health / Medicine, Experimental / Multiple Organ Failure - diagnosis / Multiple Organ Failure - drug therapy / Multiple Organ Failure - etiology / Multiple Organ Failure - physiopathology / Mycophenolic Acid - administration & dosage / Myocarditis / Myositis / Pediatrics / Pulse Therapy, Drug - methods / Rheumatologic disease / Rheumatology / Treatment Outcome / Viral antibodies / Weight loss